問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Medical University Hospital

Recruiting

List

211Cases

2025-06-09 - 2029-11-26

Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation

  • Condition/Disease

    Pulmonary Disease, Chronic Obstructive

  • Test Drug

    Prefilled Injectable

Participate Sites
8Sites

Recruiting8Sites

2025-06-13 - 2030-06-30

Active
An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]

  • Condition/Disease

    Primary Membranous Nephropathy

  • Test Drug

    Injectable frozen powder

Participate Sites
10Sites

Recruiting10Sites

2025-07-01 - 2029-06-30

Phase II

Active
PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

  • Condition/Disease

    Cervical Intraepithelial Neoplasia Grade 2/3、Human Papilloma Virus Infection Type 16

  • Test Drug

    liquid

Participate Sites
9Sites

Recruiting9Sites

2025-09-01 - 2029-12-31

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age

  • Condition/Disease

    Healthy

  • Test Drug

    Injectables

Participate Sites
6Sites

Recruiting6Sites

2025-10-09 - 2033-12-31

Phase I/II

Not yet recruiting
A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    Injectable

Participate Sites
2Sites

Recruiting2Sites

2025-08-20 - 2027-12-31

IIT

Phase IV

Not yet recruiting
An Exploratory Study to Identify Optimal Indication Criteria for the Use of Immunomodulatory Therapy in Patients with Kawasaki Disease

  • Condition/Disease

    Kawasaki Disease

  • Test Drug

    Sandimmun Neoral Solution

Participate Sites
1Sites

Recruiting1Sites

2021-09-01 - 2023-04-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

2025-08-01 - 2031-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-04-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2025-11-01 - 2030-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

1 2 3 4 5 22
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB